Eisai Inc.
Eisai Inc.
Explore linked clinical trials.40 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, adenocarcinoma, adenoid cystic carcinoma, carcinoma, epithelial neoplasm, mouth disorder, neoplasm, salivary gland cancer, salivary gland disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT04209660 | |
| A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Not stated | 2026-10-08 | NCT07864623 | |
| Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Brain Metastases, Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 2 | 2026-10-07 | NCT05064280 | |
| A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants | Healthy Volunteers | Recruiting | Phase 1 | 2026-10-06 | NCT07766369 | |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, autosomal dominant Parkinson disease 4, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT04736706 | |
| Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Not stated | 2026-09-30 | NCT07849660 | |
| How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS) | Lower Urinary Tract Symptoms, Nocturia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urological Manifestations | Not yet recruiting | Phase 4 | 2026-09-25 | NCT07840638 | |
| A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease | Alzheimer disease, Hemorrhage, Intracranial Hemorrhages, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, dementia, intracerebral hemorrhage, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy, vascular disorder, visual epilepsy | Active, not recruiting | Not stated | 2026-09-21 | NCT07723950 | |
| A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-09-16 | NCT07821658 | |
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-08-27 | NCT04288089 | |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, autosomal dominant Parkinson disease 4, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05899049 | |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 1 | 2026-08-17 | NCT07768592 | |
| A Study of Oral E1018 in Healthy Adult Participants | Infections, Mosquito-Borne Diseases, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Active, not recruiting | Phase 1 | 2026-08-07 | NCT06854042 | |
| DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-07-27 | NCT06384573 | |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-27 | NCT05269394 | |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-27 | NCT01760005 | |
| DORA and LP in Alzheimer's Disease Biomarkers | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-07-13 | NCT06274528 | |
| A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 | 2026-07-10 | NCT04015141 | |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-07-06 | NCT02623972 | |
| Merck IIT: RRP Pembro and Lenvatinib | lung disorder, recurrent respiratory papillomatosis, respiratory system disorder | Recruiting | Phase 2 | 2026-07-02 | NCT04645602 | |
| Scalp Cooling in MBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, chemotherapy-induced alopecia, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-06-18 | NCT04986579 | |
| Study of E7386 in Participants With Selected Advanced Neoplasms | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-06-08 | NCT03264664 | |
| AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | Early Preclinical Alzheimer's Disease; Preclinical Alzheimer's Disease | Active, not recruiting | Phase 3 | 2026-06-04 | NCT04468659 | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-04 | NCT04300556 |